Patents by Inventor Sobhana Babu Boga

Sobhana Babu Boga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AZIDE INSULIN ANALOGUES
    Publication number: 20230365646
    Abstract: The present invention relates to insulin analogues and processes of making such insulin analogues by direct conversion of a free amine to an azide via diazo-transfer with an azotransfer agent.
    Type: Application
    Filed: July 31, 2023
    Publication date: November 16, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Sobhana Babu Boga, Ahmet Kekec, Songnian Lin, Craig A. Parish, Weijuan Tang, Lin Yan
  • METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS
    Publication number: 20230234956
    Abstract: A process is provided for making a WEE1 inhibitor of the formula (1A) useful in the treatment of conditions characterized by excessive cellular proliferation, such as cancer. In some embodiments, processes are provided for making intermediate compounds of the formulae (3), (5) and (6) as defined herein.
    Type: Application
    Filed: June 9, 2021
    Publication date: July 27, 2023
    Inventors: Peter Qinhua Huang, Chad Daniel Hopkins, Brant Clayton Boren, Sunny Abraham, Kevin Duane Bunker, Sobhana Babu Boga, Shuguang Zhu, Tao Wu, Benjamin Pratt
  • MACROCYCLIC COMPOUNDS
    Publication number: 20230192720
    Abstract: The present application discloses compounds of Formula (I). Such compounds, pharmaceutically acceptable salts and compositions thereof, are inhibitors of Mcl-1 proteins and are useful in treating diseases and conditions characterized by excessive cellular proliferation such as cancer.
    Type: Application
    Filed: August 6, 2020
    Publication date: June 22, 2023
    Inventors: Junhu Zhang, Peter Qinhua Huang, Kevin Duane Bunker, Sobhana Babu Boga, Sunny Abraham, Brant Clayton Boren, Wanlong Jiang, Sunil Paliwal
  • PCSK9 ANTAGONIST COMPOUNDS
    Publication number: 20230159592
    Abstract: Disclosed are compounds of Formula I, or a salt thereof: where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
    Type: Application
    Filed: June 30, 2022
    Publication date: May 25, 2023
    Inventors: Harold B. Wood, Hubert B. Josien, Thomas Joseph Tucker, Angela Dawn Kerekes, Ling Tong, Abbas M. Walji, Anilkumar G. Nair, Fa-Xiang Ding, Elisabetta Bianchi, Danila Branca, Chengwei Wu, Yusheng Xiong, Sookhee Nicole HA, Jian Liu, Sobhana Babu Boga
  • CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL
    Publication number: 20230002426
    Abstract: Disclosed herein are methods for preparing tertiary alcohols from an optionally substituted phenyl ketone or an optionally substituted pyridinyl ketone that includes the use of a chiral ligand and boron trifluoride diethyl etherate. Tertiary alcohols can be used to prepare synthetic versions of natural products and/or pharmaceuticals.
    Type: Application
    Filed: November 12, 2020
    Publication date: January 5, 2023
    Inventors: Sunny Abraham, Brant Clayton Boren, Sobhana Babu Boga, Aditya Krishnan Unni, Peter Qinhua Huang, Kevin Duane Bunker, Benjamin Anthony Pratt
  • PCSK9 antagonist compounds
    Patent number: 11427616
    Abstract: Disclosed are compounds of Formula I, or a salt thereof: where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: August 30, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Harold B. Wood, Hubert B. Josien, Thomas Joseph Tucker, Angela Dawn Kerekes, Ling Tong, Abbas M. Walji, Anilkumar G. Nair, Fa-Xiang Ding, Elisabetta Bianchi, Danila Branca, Chengwei Wu, Yusheng Xiong, Sookhee Nicole Ha, Jian Liu, Sobhana Babu Boga
  • MACROCYCLIC COMPOUNDS
    Publication number: 20220144854
    Abstract: Disclosed are macrocyclic compounds of formula (I) comprising a 2-carboxy indole ring. Such compounds, and their pharmaceutically acceptable salts, are useful as Mcl-1 (myeloid cell leukemia-1) inhibitors. The compounds may be used in treating a disease or condition, such as cancer.
    Type: Application
    Filed: March 6, 2020
    Publication date: May 12, 2022
    Inventors: Junhu Zhang, Peter Qinhua Huang, Kevin Duane Bunker, Sobhana Babu Boga, Sunny Abraham, Brant Clayton Boren, Wanlong Jiang, Sunil Paliwal
  • AZIDE INSULIN ANALOGUES
    Publication number: 20210163568
    Abstract: The present invention relates to insulin analogues and processes of making such insulin analogues by direct conversion of a free amine to an azide via diazo-transfer with an azotransfer agent.
    Type: Application
    Filed: April 8, 2019
    Publication date: June 3, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sobhana Babu Boga, Ahmet Kekec, Songnian Lin, Craig A. Parish, Weijuan Tang, Lin Yan
  • PCSK9 ANTAGONIST COMPOUNDS
    Publication number: 20190389909
    Abstract: Disclosed are compounds of Formula I, or a salt thereof: where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
    Type: Application
    Filed: June 20, 2019
    Publication date: December 26, 2019
    Inventors: Harold B. Wood, Hubert B. Josien, Thomas Joseph Tucker, Angela Dawn Kerekes, Ling Tong, Abbas M. Walji, Anilkumar G. Nair, Fa-Xiang Ding, Elisabetta Bianchi, Danila Branca, Chengwei Wu, Yusheng Xiong, Sookhee Nicole HA, Jian Liu, Sobhana Babu Boga
  • Indazole and azaindazole Btk inhibitors
    Patent number: 10246457
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R7, R8 and R9 are as herein described. The present invention also provides pharmaceutical compositions comprising these compounds and methods for their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: April 2, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tony Siu, Michael D. Altman, Brian M. Andresen, Jian Liu, Joseph Kozlowski, Sobhana Babu Boga, Younong Yu, Rajan Anand, Jiaqiang Cai, Dahai Wang, Shilan Liu
  • Btk inhibitors
    Patent number: 10214546
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: February 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jian Liu, Joseph A. Kozlowski, Sobhana Babu Boga, Xiaolei Gao, Deodial Guy Guiadeen, Jiaqiang Cai, Shilan Liu, Dahai Wang, Hao Wu, Chundao Yang
  • Tertiary alcohol imidazopyrazine BTK inhibitors
    Patent number: 10208047
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, Formula I or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: February 19, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jian Liu, Joseph A. Kozlowski, Brian M. Andresen, Sobhana Babu Boga, Xiaolei Gao, Deodial Guy Guiadeen, Jiaqiang Cai, Shilan Liu, Dahai Wang, Hao Wu, Chundao Yang
  • BTK inhibitors
    Patent number: 10130630
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: November 20, 2018
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Jian Liu, Joseph A. Kozlowski, Abdul-Basit Alhassan, Rajan Anand, Sobhana Babu Boga, Deodial Guy Guiadeen, Wensheng Yu, Younong Yu, Shilan Liu, Hao Wu, Chundao Yang
  • Benzamide imidazopyrazine Btk inhibitors
    Patent number: 10087188
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: October 2, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jian Liu, Joseph A. Kozlowski, Abdul-Basit Alhassan, Sobhana Babu Boga, Xiaolei Gao, Deodial Guy Guiadeen, Jyhshing Wang, Wensheng Yu, Jiaqiang Cai, Shilan Liu, Dahai Wang, Hao Wu, Chundao Yang
  • AZACARBAZOLE BTK INHIBITORS
    Publication number: 20180141962
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein CH, R1, R1a, R1b, R2, R3, and the subscripts m1, m2, p, q, and t are as set forth herein. The present invention also provides pharmaceutical compositions comprising these compounds and their use in therapy. In Cparticular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated dis orders.
    Type: Application
    Filed: April 4, 2016
    Publication date: May 24, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JIAN LIU, JOSEPH KOZLOWSKI, RONALD KIM, XIAOLEI GAO, SOBHANA BABU BOGA, YOUNONG YU, HAO WU, SHILAN LIU, CHUNDAO YANG
  • INDAZOLE AND AZAINDAZOLE BTK INHIBITORS
    Publication number: 20180127411
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R7, R8 and R9 are as herein described. The present invention also provides pharmaceutical compositions comprising these compounds and methods for their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    Type: Application
    Filed: April 4, 2016
    Publication date: May 10, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Tony SIU, Michael D. ALTMAN, Brian M. ANDRESEN, Jian LIU, Joseph KOZLOWSKI, Sobhana Babu BOGA, Younong YU, Rajan ANAND, Jiaqiang CAI, Dahai WANG, Shilan LIU
  • BTK INHIBITORS
    Publication number: 20180118766
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    Type: Application
    Filed: December 17, 2015
    Publication date: May 3, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JIAN LIU, JOSEPH A. KOZLOWSKI, SOBHANA BABU BOGA, XIAOLEI GAO, DEODIAL GUY GUIADEEN, JIAQIANG CAI, SHILAN LIU, DAHAI WANG, HAO WU, CHUNDAO YANG
  • BTK INHIBITORS
    Publication number: 20180079752
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.
    Type: Application
    Filed: May 31, 2016
    Publication date: March 22, 2018
    Applicants: MERCK SHARP & DOHME CORP., MERCK SHARP & DOHME B.V.
    Inventors: ADRIANUS PETRUS ANTONIUS DE MAN, RONALD KIM, JIAN LIU, JOSEPH A. KOZLOWSKI, SOBHANA BABU BOGA, THIERRY FISCHMANN, DEODIAL Guy GUIADEEN, ILSE HENDRICA MARIA POLS-DE ROOIJ, SHILAN LIU, HAO WU
  • BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS
    Publication number: 20170362242
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    Type: Application
    Filed: December 17, 2015
    Publication date: December 21, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JIAN LIU, JOSEPH A. KOZLOWSKI, ABDUL-BASIT ALHASSAN, SOBHANA BABU BOGA, XIAOLEI GAO, DEODIAL GUY GUIADEEN, JYHSHING WANG, WENSHENG YU, JIAQIANG CAI, SHILAN LIU, DAHAI WANG, HAO WU, CHUNDAO YANG
  • BIARYLETHER IMIDAZOPYRAZINE BTK INHIBITORS
    Publication number: 20170362243
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    Type: Application
    Filed: December 17, 2015
    Publication date: December 21, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JIAN LIU, JOSEPH A. KOZLOWSKI, SOBHANA BABU BOGA, XIAOLEI GAO, DEODIAL GUY GUIADEEN, JYHSHING WANG, SHILAN LIU